

# DOPING CONTROL GUIDE

Untuk ASEAN  
Para Games 2022  
Solo, Indonesia




11<sup>th</sup> ASEAN  
PARA GAMES  
SOLO 2022



Inasporc

*Striving  
Equality*



## **Message from PRESIDENT**

### **ASEAN Para Sports Federation (APSF)**

#### **Greetings and welcome to Solo!**

I'm delighted to be able to pen a few words for this Doping Control Guide for the 11th ASEAN Para Games 2022 which will take place in the beautiful city of Solo from 30th July to 6th August. It is such a pleasure that we are able to gather and reunite for the Games after a lapse of four years. Indeed, we are deeply honored to have every nation joining us to celebrate the biennial sporting extravaganza which will see the participation of more than 1,300 athletes from all 11 nations.

On behalf of the ASEAN Para Sports Federation (APSF) and the Paralympic family, allow me to thank our local organisers, the Indonesia ASEAN Para Games Organising Committee (INASPOC) for all the efforts in preparing and delivering the Games following Hanoi's withdrawal from the hosting job last year.

I would like to express my sincere appreciation to INASPOC, NPC Indonesia and the relevant stakeholders who have come together with APSF to ensure all organizational aspects of the Games are well placed. The emphasis given on ensuring fair play during competition is laudable and this includes ensuring strict anti-doping measures which include testing on the usage of banned substances during Games time.

Anti-doping exercise is an important aspect of any Games as it is part of a global effort to promote, coordinate, and monitor the fight against drugs in sports. The usage of banned substances and performance-enhancing drugs during competition is simply unethical, going against the "spirit of sport" and therefore, prohibited by most international sports organizations, including the International Paralympic Committee (IPC). Regionally, APSF, in collaboration with the Asian Paralympic Committee (APC) and INASPOC, will continue to conduct tests and collection of samples to ensure a clean Games.

In conclusion, I would like to record my gratitude to INASPOC, Indonesia Anti-Doping Organization (IADO) and the Asian Paralympic Committee (APC) for working together with the APSF Anti-Doping Committee to ensure that the doping programme for the Games is effectively carried out in line with the World Anti-Doping Code requirements. To all officials, volunteers and staff involved, I thank you for your tireless efforts in helping to ensure a clean Games.

I wish you all the best, Matur nuwun and Thank You!

**MAJ GEN OSOTH BHAVILAI**

**President**

## CONTENTS

<b>A. OVERVIEW OF THE ANTI-DOPING PROGRAMME</b>	<b>4</b>
1. GOVERNANCE OF THE INDONESIA ASEAN PARA GAMES ORGANISING COMMITTEE (INASPOC).	4
2. IN-COMPETITION AND OUT-OF-COMPETITION TESTING	5
3. LABORATORY	5
4. SUPPLEMENT USE	6
5. PROHIBITED LIST	6
6. MEDICATION USE	6
7. GUIDELINES FOR THERAPEUTIC USE EXEMPTION (TUE)	7
8. ATHLETE WHEREABOUTS INFORMATION	9
9. USE OF CATHETERS	10
<b>B. TECHNICAL PROCEDURES FOR DOPING CONTROL</b>	<b>11</b>
1. INTRODUCTION	11
2. SELECTION OF ATHLETES	11
3. NOTIFICATION OF ATHLETES	12
4. REQUIREMENTS FOR NOTIFICATION OF ATHLETE	15
5. PREPARING FOR THE SAMPLE COLLECTION SESSION	19
6. CONDUCTING THE SAMPLE COLLECTION SESSION	22
7. SECURITY/POST-TEST ADMINISTRATION	27
8. TRANSPORT OF SAMPLES AND DOCUMENTATION	29
9. OWNERSHIP OF SAMPLES	32
<b>ANNEX</b>	<b>33</b>
<b>ANNEX A: INVESTIGATING A POSSIBLE FAILURE TO COMPLY</b>	<b>33</b>
<b>ANNEX B: MODIFICATIONS FOR ATHLETES WITH IMPAIRMENTS</b>	<b>36</b>
<b>ANNEX C: MODIFICATIONS FOR ATHLETES WHO ARE MINORS</b>	<b>38</b>
<b>ANNEX D: COLLECTION OF URINE SAMPLES</b>	<b>41</b>
<b>ANNEX E: COLLECTION OF BLOOD SAMPLES</b>	<b>46</b>
<b>ANNEX F: URINE SAMPLES - INSUFFICIENT VOLUME</b>	<b>50</b>
<b>ANNEX G: URINE SAMPLES THAT DO NOT MEET THE REQUIREMENT FOR SUITABLE SPECIFIC GRAVITY FOR ANALYSIS</b>	<b>53</b>
<b>ANNEX H: SAMPLE COLLECTION PERSONNEL REQUIREMENTS</b>	<b>56</b>
<b>APPENDIX</b>	<b>59</b>
<b>APPENDIX 1: DEFINITIONS</b>	<b>59</b>
<b>APPENDIX 2: THERAPEUTIC USE EXEMPTIONS FORM</b>	<b>68</b>
<b>APPENDIX 3: ORGANIZATION</b>	<b>74</b>

## ASEAN Para Games XI Surakarta 2022

**A. OVERVIEW OF THE ANTI-DOPING PROGRAMME**

The objective of this Doping Control Guide is to provide each Athlete, Athlete Support Personnel and National Paralympic Committee (NPC) a clear understanding of the rules and procedures for Doping Control during the ASEAN Para Games XI Surakarta

**In particular, this Guide provides:**

- An overview of the Anti-Doping Program for the Games.
- The Technical Procedures for Doping Control for the Games.

# **1. GOVERNANCE OF THE INDONESIA ASEAN PARA GAMES ORGANISING COMMITTEE (INASPOC).**

## **1.1 APSF and ASIAN Paralympic Committee (APC) are responsible for:**

Directing the ASEAN Paragames XI Surakarta Anti- Doping Program; and both Out-of-Competition and In-competition testing from the official opening of the Official Games Hotel on **30 July 2022** to the official closing of the Official Games Hotel on **6 August 2022**.

- a. The Indonesia ASEAN Para Games Organizing Committee (INASPOC) is responsible for:
  1. The implementation of the Games Anti-Doping Program.
  2. The operations and infrastructure to enable doping control testing.
  3. Being the exclusive Sample Collection Agency (SCA) for testing at all venues
  4. To ensure the safety and security of both the Athletes and the doping control samples through the entire doping control process.

- b. The APC has established the APC Anti-Doping Rules 2021 in compliance with the World Anti-Doping Code (the “Code”) and the various International Standards.
- c. The APC Anti-Doping Rules 2021 shall apply to the Games from Athletes participating in the Games from **30 July 2022 - 6 August 2022** may be tested by the APC anywhere without any advance notice during the entire period. All participants (Athletes and Athlete Support Personnel) shall accept the APC Anti-Doping Rules as a condition of participation and are presumed to have agreed to comply with the APC Anti-Doping Rules 2021.
- d. APC Anti-Doping Committee is responsible for all anti-doping rules applicable to the Games.
- e. The APC Anti-Doping Committee is responsible for administering the provision of the APC Anti-Doping Rule, as well as the Therapeutic Use Exemptions (TUE) rules as outlined in APC Anti-Doping Rules.

## 2. IN-COMPETITION AND OUT-OF-COMPETITION TESTING

Both In-Competition testing and Out-of-Competition testing screening of urine and blood samples collected from Athletes will apply throughout the Games.

## 3. LABORATORY

Samples collected by Doping Control Division, INASPOC will be analyzed at the WADA-accredited laboratory. The Laboratory will provide test results to the APC and the World Anti-Doping Agency (WADA). Generally, test results will be provided within 10 working days after arrival in the laboratory. Samples collected on the last day of operations of the Official Games Hotel will

still be subject to analysis. Any anti-doping rule violation discovered as a result of that analysis shall be dealt with under the APC Anti-Doping Rule.

#### **4. SUPPLEMENT USE**

The manufacturing and labeling of dietary supplements in many countries are not strictly regulated. This may lead to substances prohibited in sport being added deliberately during the manufacturing process or included inadvertently through contamination. Athletes who take dietary supplements are at risk of committing an anti-doping rules violation whether its use was intentional or not. Under the World Anti-Doping Code's principle of strict liability, Athletes are ultimately responsible for any substance found in their body, regardless of how it got there.

#### **5. PROHIBITED LIST**

The WADA 2022 Prohibited List that contains the substances and methods prohibited for use in sport shall apply to the Games. A copy of the 2021 Prohibited List can be found at the WADA official website (<http://www.wada-ama.org>). All Athletes and Athlete Support Personnel need to familiarize themselves with the Prohibited List.

#### **6. MEDICATION USE**

It is the responsibility of the Athlete to determine whether a substance he/she is using or considering using is prohibited. At all times, Athletes are strongly advised to check the status of all medications with their team doctors, or through drug databases available online by some National Anti-Doping Organizations (NADOs), such as:

Global Drug Reference Online (Global DRO)	<a href="http://www.globaldro.com/">http://www.globaldro.com/</a>
Hong Kong Anti-Doping Committee - Drug in Sport (HKADC)	<a href="http://www.druginsport.hk">http://www.druginsport.hk</a>

If the medication an Athlete is required to take for treating an illness or condition is listed on the Prohibited List, the Athlete should either switch to a permitted alternative or obtain a Therapeutic Use Exemption (TUE) to take the required medication. All Athletes competing at the Games who need a TUE are expected to have applied to their relevant International Federation (IF) or National Anti-Doping Organization (NADO), so that the TUE is granted no later than the day before the official Opening Ceremony of the Games. Only for those NPCs that do not have NADO in their respective countries can apply for their TUE to the APC TUE Committee (TUEC) (Please refer 7.4).

## 7. GUIDELINES FOR THERAPEUTIC USE EXEMPTION (TUE)

- 7.1** Athletes with a documented medical condition requiring the use of a Prohibited Substance or Prohibited Method must obtain a TUE by submitting a TUE application in advance of the Games to their IF, NADO or APC TUEC.
- 7.2** Athletes granted approval of a TUE by their IF or NADO, are required to submit and provide a copy of the approval to APC Therapeutic Use Exemption Committee (APC TUEC) at least thirty (30) days before the opening of the Official Games Hotel. As such, the APC TUEC must receive a copy of approved TUE by **30 June 2022**.

- 7.3** The APC TUEC will recognize TUEs issued in compliance with the Code by the IF and NADO but reserves the right to review the TUE at its sole discretion.
- 7.4** Athletes belonging to an IF/NPC that does not have a mechanism to issue TUEs and representing a country without a NADO should submit their TUE application with all supporting documents to the APC TUEC at least thirty (30) days before the start of the Games. As such, the APC TUEC must receive all TUE applications and documents by **30 June 2022**. Refer to the Therapeutic Use Exemption Application Form).
- 7.5** The Chairperson of the APC Anti-Doping Committee will appoint APC TUEC members for the ASEAN Para Games XI Surakarta to monitor existing TUEs granted to Athletes by their IF or NADO and to consider new TUE applications. The TUEC shall promptly evaluate and decide upon the application in accordance with the relevant provisions of the *International Standard for Therapeutic Use Exemptions* and usually (i.e., unless exceptional circumstances apply) within no more than **twenty-one (21) days** of receipt of a complete application. Where the application is made in a reasonable time prior to an *Event*, the TUEC must use its best endeavors to issue its decision before the start of the *Event*.
- 7.6** The APC TUEC will promptly inform the Athlete, the Athlete's NPC, WADA and the relevant IF of its decision. A decision granting a TUE can be appealed by WADA.

7.7 All approved TUEs granted by the IF or NADO and TUE applications are to be submitted to: APC TUEC ([tue@asianparalympic.org](mailto:tue@asianparalympic.org))

## 7.8 Emergency TUE

7.8.1. The APC TUEC will only consider a retroactive TUE application for a prohibited substance and/or method used during the Games if the prohibited substance and/or method given by a physician:

- a. was used in an emergency situation or:
- b. the treatment of an acute medical condition was necessary.

7.8.2. Emergency TUE applications must be submitted immediately to the APC TUEC.

## 7.9 Emergency Treatment

In the event of an emergency treatment of an acute medical condition provided to an Athlete resulting in the administration of a Prohibited Substance, the attending physician (either from INASPOC or the NPC) is responsible for completing a TUE application form. This form will be available at the Medical Centre / Medical Station/ Refer Hospital and also at the various centers providing medical services for the Games. The form must be completed as soon as possible after the incident and submitted to Medical Command Centre or to APC TUEC at Doping Control Centre in the Official Games Hotel ([tue@asianparalympic.org](mailto:tue@asianparalympic.org))

## 8. ATHLETE WHEREABOUTS INFORMATION

The APC, as a Signatory to the Code, as well as INASPOC recognize that effective out-of-competition testing program are essential to the fight against doping in sport. They also recognize

that effective out-of-competition testing depends upon accurate and complete athlete whereabouts information.

The APC and INASPOC therefore request all NPCs:

INASPOC requires each NPC to submit room list of athletes and competition partners instead of whereabouts information.

These components are of paramount importance to enable locating athletes for testing in the lead up to the competition period. In the event that the information received from the NPCs is incomplete, or when NPCs refrain from sharing the information with the APC and INASPOC, the APC has the right to ask the NPC for more detailed whereabouts information.

The whereabouts information form can be obtained at Delegation Registration Meeting (DRM) and Medical Centre in the Official Games Hotel, and NPCs could submit their whereabouts information to Secretariat of Doping Control Centre in the Official Games Hotel or by e-mail to ( [tue@asianparalympic.org](mailto:tue@asianparalympic.org) )

## 9. USE OF CATHETERS

The APC consider the catheter and used by an athlete with their need for self-catheterization as 'personal equipment'. Athletes might react adversely to different brands and models, potentially leading to discomfort, infections and/or allergic reactions. Athletes therefore mainly use one particular type of catheter. Furthermore, due to the variety of brands, models, and sizes, it cannot be expected that INASPOC or Doping Control Officers (DCO) will supply catheters that meet the individual requirements of each athlete.

Within this perspective, and giving absolute priority to the athlete's health, the catheter used is the responsibility of the athlete.

Although not mandatory, the APC and INASPOC strongly

advised athletes to use sterile catheters for hygiene reasons and in accordance with the manufacturer's instructions. They have instructed DCOs to report if a non-sterile catheter has been used.

The use of a catheter must comply with the criteria set forth in the WADA IST, Annex B: Modifications for Athletes with impairments.

## **B. TECHNICAL PROCEDURES FOR DOPING CONTROL**

### **1. INTRODUCTION**

The purpose of these Technical Procedures for Doping Control is to plan for effective testing and to maintain the integrity and identity of the samples collected, from the point the Athlete is notified of the test, to the point the samples are transported to the laboratory for analysis. This section details the procedures for the selection, notification, and collection of urine and blood samples for doping control purposes.

The Anti-Doping Program for the Games complies with the World Anti-Doping Code and the various International Standards. Under the APC's authority, Doping Control Division, INASPOC shall implement these Technical Procedures established according to the International Standard for Testing and Investigations (ISTI).

### **2. SELECTION OF ATHLETES**

For the Games, the Chairperson of the APC Anti-Doping Committee, in consultation with Doping Control Division, INASPOC, will determine the number of doping control tests to be performed across the different sports and across the different disciplines within a sport. This will constitute the basis of the Test Distribution Plan (TDP) and shall at a minimum evaluate the potential risk of doping and possible doping patterns for each and/or discipline minimally. The APC Anti-Doping Committee may also select Athletes or teams

for target testing, as long as such target testing is not used for the purpose other than legitimate Doping Control process. The WADA Technical Document for Sport Specific Analysis (TDSSA ver 6.0) shall apply.

- 2.1. All Athletes participating in the Games will be subjected to Doping Controls initiated by the APC at any time and any place with no advance notice during the Games.

### 3. NOTIFICATION OF ATHLETES

#### 3.1. OBJECTIVE

3.1.1. To ensure that reasonable attempts are made to locate and notify the Athlete while maintaining the Athlete's rights; and at the same time ensuring that there are no opportunities for the Athlete to manipulate the samples provided.

#### 3.2. GENERAL

3.2.1. Notification of Athletes starts when Chaperone of Doping Control Division, INASPOC initiates the notification of the selected Athlete and ends when the Athlete arrives at the Doping Control Station or when the Athlete's possible "Failure to Comply" is brought to the attention of the APC.

The main activities are:

- appointment of DCOs, Chaperones and other Sample Collection Personnel;
- locating the Athlete and confirming his/her identity;
- informing the Athlete that he/she has been selected to provide a sample and of his/her rights and responsibilities;

- for No Advance Notice Testing, continuously chaperoning the Athlete from the time of notification to the arrival at the designated Doping Control Station; and
- documenting the notification, or notification attempt.

### **3.3. REQUIREMENTS PRIOR TO NOTIFICATION OF ATHLETE**

3.3.1. No Advance Notice shall be the notification method for Sample Collection whenever possible.

3.3.2. The Doping Control Division, INASPOC shall appoint and authorize Sample Collection Personnel to conduct or assist with Sample Collection Sessions who have been trained for their assigned responsibilities; who do not have a conflict of interest in the outcome of the sample collection; and who are not Minors.

3.3.3. Doping Control Officers (DCOs) and Chaperones will be given the official Games (photo identification) accreditation pass controlled by INASPOC. This pass will help Athletes identify the DCOs and Chaperones whilst they carry out their official duties during the Games.

3.3.4. Athletes selected for Doping Control will be identified by their assigned Games accreditation pass. If that is not available, the Athlete's passport can be used as an alternative form of photographic identification.

3.3.5. An Athlete shall be identified through third-party identification only if a photographic identification for that Athlete is not available. This could include

the Athlete being identified by technical delegates, opponent team or coach. This person shall sign the Doping Control Form as an acknowledgement that he/she had identified the Athlete.

3.3.6. The method of identification of the Athlete shall be documented on the Doping Control form.

3.3.7. The Athlete shall be the first one to be notified if he/she has been selected for Doping Control, except where prior contact with a third party is required

3.3.8. The DCO/Chaperone shall consider whether a third party is required to be notified prior to notification of the Athlete. This may include situations where required by an Athlete's Impairment (as provided for in Annex B: Modifications for Athletes with Impairments), or where the Athlete is a Minor (as provided for in Annex C: Modifications for Athlete who are Minors, or in situation where an interpreter is required and available for the notification.

3.3.9. In exceptional circumstances, Doping Control Division, INASPOC or the DCO may change a sample collection from No Advance Notice to Advance Notice. Any such occurrence shall be recorded.

#### 4. REQUIREMENTS FOR NOTIFICATION OF ATHLETE

4.1.1. The DCO/Chaperone will notify the selected Athlete when the Athlete leaves the Field of Play following the Competition or after the final results are declared. Where possible, if an Athlete is participating in future Competition on the same day, they will be notified at the end of their Competition schedule for that day.

4.1.2. When initial contact is made, the DCO/Chaperone shall ensure that the Athlete and/or a third party, if required, is informed:

- have a representative and, if available, an interpreter.
- ask for additional information about the sample collection process.
- request a delay in reporting to the Doping Control Station for valid reasons; and
- request modifications as provided for in Annex B: Modifications for Athletes with Impairments.
- of the Athlete's responsibilities, including the requirement to:
  - remain within sight of the DCO/Chaperone at all times from the first moment of in-person notification by the DCO/Chaperone until the completion of the sample collection procedure;
  - produce identification
  - comply with the sample collection procedures and the possible consequences of Failure to Comply: and
  - report immediately for a test, unless delayed for valid reasons;

- of the location of the Doping Control Station;
- that should the Athlete choose to consume food or fluids prior to providing a sample, he/she does so at his/her own risk;
- that the Athlete should avoid excessive rehydration, having in mind the requirement to produce a sample with a suitable Specific Gravity for analysis; and
- that the sample provided by the Athlete to the Sample Collection Personnel should be the first urine passed by the Athlete subsequent to notification, i.e he/she should not pass urine in the shower or otherwise prior to providing a sample to the Sample Collection Personnel.

4.1.3. After contact is made, the DCO/Chaperone shall:

- keep the Athlete under observation at all times until the completion of his/her Sample Collection Session:
- identify themselves to the Athlete using their Official Games accreditation pass; and
- collect the Athlete's Games accreditation pass to assist in identifying and confirming the Athlete's identity.
- The inability to confirm the identity of the Athlete shall be documented. In such cases, the DCO responsible for conducting the Sample Collection Session shall decide whether it is appropriate to report the situation in accordance with Annex A: Investigating a Possible Failure to Comply. The Athlete's Games accreditation pass shall be returned to the Athlete when the process is completed.

4.1.4. The DCO/Chaperone shall have the Athlete sign an appropriate form to acknowledge and accept the notification. If the Athlete refuses to sign that he/ she has been notified or evades the notification, the DCO/Chaperone shall inform the Athlete of the consequences of a Failure to Comply if possible, and the Chaperone (if not the DCO) shall immediately report all relevant facts to the DCO. The DCO shall persuade the Athlete and when the Athlete agree they should continue to collect a sample. The DCO shall document the facts and report the circumstances to the Anti-Doping Venue Manager (DVM) or Lead DCO as soon as possible if the athlete does not comply. The DVM/Lead DCO shall inform the Doping Control Division INASPOC, who will then inform the APC. The APC shall follow the steps prescribed in Annex A: Investigating a Possible Failure to Comply.

4.1.5. The DCO/Chaperone may at their discretion consider any valid third party requirement or any valid request by the Athlete for permission to delay reporting to the Doping Control Station following acknowledgement and acceptance of notification, and/or to leave the Doping Control Station temporarily after arrival, and may grant such permission if the Athlete can be continuously chaperoned and kept under direct observation during the delay and if the request relates to the following activities:

- participation in a victory ceremony;
- fulfilment of media commitments;
- competing in further Competitions;
- performing a warm down;

- obtaining necessary medical treatment;
- locating a representative and/or interpreter;
- obtaining photo identification; or
- any other exceptional circumstances which can be justified, and which shall be documented.

4.1.6. The DCO or other Sample Collection Personnel shall document the reasons for a delay in reporting to the Doping Control Station and/or reasons for leaving the Doping Control Station once arriving that may require further investigation by the INASPOC. Any failure by the Athlete to remain under constant observation should be recorded.

4.1.7. A DCO/Chaperone shall reject a request for delay from an Athlete if it will not be possible for the Athlete to be continuously chaperoned.

4.1.8. If the Athlete delays reporting to the Doping Control Station other than in accordance with Article 3.4.5 but arrives prior to the DCO's departure, the DCO shall decide whether to report a possible Failure to Comply. If at all possible, the DCO shall proceed with collecting a Sample and shall document the details of the delay in the Athlete reporting to the Doping Control Station.

4.1.9. If, while keeping the Athlete under observation, Sample Collection Personnel observes any matter with potential to compromise the test, the circumstances shall be reported to and documented by the DVM / Lead

DCO. If deemed appropriate, the DVM / Lead DCO shall follow the requirements of Annex A: Investigating a Possible Failure to Comply and/or consider if it is appropriate to collect an additional Sample from the Athlete.

## **5. PREPARING FOR THE SAMPLE COLLECTION SESSION**

### **5.1. OBJECTIVE**

To prepare for the Sample Collection Session in a manner that ensures that the session can be conducted efficiently and effectively.

### **5.2. GENERAL**

5.2.1. Preparing for the Sample Collection Session starts with the establishment of a system for obtaining relevant information for effective conduct of the session and ends when it is confirmed that the Sample Collection Equipment conforms to the specified criteria

5.2.2. The main activities are:

- establishing a system for collecting details regarding the Sample Collection Session;
- establishing criteria for who may be present during a Sample Collection Session;
- ensuring that the Doping Control Station meets the minimum criteria prescribed in Article 4.3.2;
- and ensuring that Sample Collection Equipment used by INASPOC meets the minimum criteria prescribed in Article 4.3.4.

### 5.3. REQUIREMENTS FOR PREPARING FOR THE SAMPLE COLLECTION SESSION

- 5.3.1. INASPOC shall obtain all the necessary information to ensure that the Sample Collection Session can be conducted effectively and efficiently, including special requirements to meet the needs of Athletes with impairments as provided in Annex B: Modifications for Athletes with Impairments, as well as the needs of Athletes who are Minors as provided in Annex C: Modifications for Athletes who are Minors.
- 5.3.2. INASPOC shall provide Doping Control Stations that at a minimum ensures the Athlete's privacy and where possible is used solely as a Doping Control Station for the duration of the Sample Collection Session. The DCO shall record any significant deviations from the criteria.
- 5.3.3. Doping Control Stations will be located at competition venues. The DVM / Lead DCO is responsible for managing the Doping Control operations and the Doping Control workforce at a venue in the Doping Control Station.
- 5.3.4. These procedures establish minimum criteria for whom may be present during the Sample Collection Session in addition to the Sample Collection Personnel and members of the Doping Control Division INASPOC, including:
- the Athlete's entitlement to be accompanied by a representative and/or interpreter during the Sample Collection Session except when the Athlete is passing a urine Sample;

- a Minor Athlete's entitlement (as provided for in Annex C: Modifications for Athletes who are Minors), and the witnessing DCO/Chaperone's entitlement to have a representative observe the witnessing DCO/Chaperone when the Minor Athlete is passing a urine Sample, but without the representative directly observing the passing of the Sample unless requested to do so by the Minor Athlete;
- an Athlete with an impairment's entitlement to be accompanied by a representative as provided in Annex B: Modifications for Athletes with Impairments; and

5.3.5. INASPOC shall only use Sample Collection Equipment systems which at a minimum:

- have a unique numbering system incorporated into all bottles, containers, tubes or any other item used to seal the Athlete's Sample;
- have a sealing system that is tamper evident;
- ensure the identity of the Athlete is not evident from the equipment itself; and be clean and sealed prior to use by the Athlete.

5.3.6. INASPOC will use LockCon (or other WADA approved alternatives) Sample Collection Equipment.

5.3.7. Photographs, video or tape recordings may only be taken inside the Doping Control Station with the permission of the DVM / Lead DCO and only when the Doping Control Station is not in operation. No photographs, video or tape recordings may be taken once the Doping

Control Station is in operation. Mobile phones may be used as phones but not cameras. However, all mobile phones must be turned off during the processing of the Sample.

## **6. CONDUCTING THE SAMPLE COLLECTION SESSION**

### **6.1. OBJECTIVE**

6.1.1. To conduct the Sample Collection Session in a manner that ensures the integrity, security and identity of the Sample and respects the privacy of the Athlete.

### **6.2. GENERAL**

6.2.1. The Sample Collection Session starts with defining the overall responsibility for the conduct of the Sample Collection Session and ends once the Sample collection documentation is complete.

6.2.2. The main activities are:

- preparing for collecting the Sample;
- collecting and securing the Sample; and documenting the Sample Collection.

### **6.3. REQUIREMENTS PRIOR TO SAMPLE COLLECTION**

6.3.1. INASPOC shall be responsible for the overall conduct of the Sample Collection Session with specific responsibilities delegated to the DCO.

6.3.2. The DCO shall ensure that the Athlete is informed of his/her right and responsibilities as specified in Article 3.4.2.

- 6.3.3. The DCO shall provide the Athlete with the opportunity to hydrate. The Athlete should avoid excessive hydration, having in mind the requirement to provide a Sample with a Suitable Specific Gravity for Analysis.
- 6.3.4. The Athlete shall only leave the Doping Control Station under continuous observation by the DCO/Chaperone and with the approval of the DVM/Lead DCO. The DVM/Lead DCO shall consider any reasonable request, as specified in Article 3.4.5 and 3.4.6, by the Athlete to leave the Doping Control Station, until the Athlete is able to provide a Sample.
- 6.3.5. If the DVM/Lead DCO gives approval for the Athlete to leave the Doping Control Station, the DVM/Lead DCO shall agree with the Athlete on the following conditions of leave:
- the purpose of the Athlete leaving the Doping Control Station;
  - the time of return (or return upon completion of an agreed activity);
  - that the Athlete must remain under observation at all times; and
- 6.3.6. that the Athlete shall not pass urine until he/she gets back to the Doping Control Station.
- 6.3.7. The DCO shall document this information agreed to and the actual time of the Athlete's departure and subsequent return.

**6.4. REQUIREMENTS FOR SAMPLE COLLECTION**

6.4.1. The DCO shall collect the Sample from the Athlete according to the following procedures for the specific type of Sample collection:

- Annex D: Collection of Urine Samples
- Annex E: Collection of Blood Samples

6.4.2. Any behavior by the Athlete and/or Persons associated with the Athlete or anomalies with potential to compromise the Sample collection shall be recorded by the DCO. If appropriate, INASPOC and/ or DCO shall apply Annex A: Investigating a Possible Failure to Comply.

6.4.3. If there are doubts as to the origin or authenticity of the Sample, the Athlete shall be asked to provide an additional Sample. If the Athlete refuses to provide an additional Sample, the DCO shall document in detail the circumstances around the refusal and INASPOC shall apply Annex A: Investigating a Possible Failure to Comply.

6.4.4. The DCO shall provide the Athlete with the opportunity to document any concerns he/she may have about how the Sample Collection Session was conducted.

6.4.5. In conducting the Sample Collection Session, the following information shall be recorded as a minimum:

- date, time and type of notification (No Advance Notice, Advance Notice, in- or out-of-competition);

- arrival time at Doping Control Station;
- date and time of completion of Sample collection process (i.e., the time when the Athlete signs the declaration at the bottom of the Doping Control form);
- name of the Athlete;
- date of birth of the Athlete;
- gender of the Athlete;
- athlete' s home address, email address and telephone number;
- athlete' s sport and discipline;
- name of the Athlete's coach and doctor;
- sample Code Number
- type of the Sample (urine, blood, etc);
- type of test (In-Competition or Out-of-Competition);
- name and signature of the Chaperone or DCO who witnessed the urine Sample provision
- name and signature of the Blood Collection Officer who collected the blood Sample, where applicable;
- Partial Sample information;
- required laboratory information on the Sample;
- medications and supplements taken within the previous seven days and blood transfusions within the previous three months, if applicable, as declared by the Athlete;
- any irregularities in procedures;
- Athlete comments or concerns regarding the conduct of the Sample Collection Session, as declared by the Athlete;
- Athlete consent for the processing of Sample collection data;

- athlete consent, or refusal to consent, for the use of the Sample(s) for research purposes;
- name and signature of the Athlete;
- name and signature of the Athlete's representative, if applicable; and
- name and signature of the DCO; and
- DCO comments for any Modifications to the sample collection process.

6.4.6. At the conclusion of the Sample Collection Session, the Athlete and DCO shall sign appropriate documentation to indicate their satisfaction; and that the documentation accurately reflects the details of the Athlete's Sample Collection Session, including any concerns recorded by the Athlete. The Athlete's representative (if any) and the Athlete shall both sign the documentation if the Athlete is a Minor. Other Persons present who had a formal role during the Athlete's Sample Collection Session may sign the documentation as a witness of the proceedings.

6.4.7. The DCO shall provide the Athlete with a copy of the records of the Sample Collection Session that have been signed by the Athlete.

## **7. SECURITY/POST-TEST ADMINISTRATION**

### **7.1. OBJECTIVE**

- 7.1.1. To ensure that all Samples collected at the Doping Control Station and Sample Collection Documentation are securely stored prior to their dispatch from the Doping Control Station.

### **7.2. GENERAL**

- 7.2.1. Post-Test Administration begins when the Athlete leaves the Doping Control Station after providing a Sample and ends with preparation of all of the collected Samples and documentation for transport.

### **7.3. REQUIREMENTS FOR SECURITY / POST-TEST ADMINISTRATION**

- 7.3.1. INASPOC has established criteria to ensure that any Sample will be stored in a manner that protects its integrity, identity and security prior to transport from the Doping Control Station. The DCO shall ensure that any Sample is stored in accordance with these criteria. These criteria are ensuring that the samples are placed in a lockable refrigerator within the Doping Control Station prior to transport.

- **Athlete Sign-Out**

Once the Athlete has fulfilled all the sample collection requirements and has been given a copy of the Doping Control Form, the Athlete will be chaperoned to the Registration Desk and required to sign-out of the Doping Control Station. The Athlete Games Accreditation Pass will only be returned after the sign-out process has completed.

- Sample and Doping Control Form Security

Once the Sample has been sealed, it will normally be secured in a lockable fridge in the Doping Control Station. If a lockable fridge is not available, urine Samples will be stored in a cool place in the Doping Control Station. All completed forms shall be kept in a secure manner.

- Sample Session Documentation

At the end of the doping control session or when a scheduled pick-up of samples is due, the DVM / Lead DCO will be responsible for completing all post session documentation and sealing of all samples in a courier transportation box for pick- up. Post session documentation include:

- Doping Control Forms
- Supplementary Report Forms
- DCO Report Form
- Chain of Custody Form

7.3.2. Without exception, all Samples collected shall be sent for analysis to a WADA-accredited laboratory or as otherwise approved by WADA.

7.3.3. The DCO shall ensure that the documentation for each Sample is completed and securely handled.

7.3.4. INASPOC shall ensure that, where required, instructions for the type of analysis to be conducted are provided to the WADA-accredited laboratory.

## **8. TRANSPORT OF SAMPLES AND DOCUMENTATION**

### **8.1. OBJECTIVE**

8.1.1. To ensure that Samples and related documentation arrive at the WADA-accredited laboratory in proper condition to do the necessary analysis.

8.1.2. To ensure the Sample Collection Session documentation is sent by the DVM / Lead DCO to the APC in a secure and timely manner.

### **8.2. GENERAL**

8.2.1. Transport starts when the Samples and Documentation leave the Doping Control Station and ends with the confirmed receipt of the Samples and Sample Collection Documentation at their intended destinations.

8.2.2. The main activities are arranging for the secure transport of Samples and related documentation to the WADA-accredited laboratory and arranging for the secure transport of Sample Collection Documentation to the APC.

### **8.3. REQUIREMENTS FOR TRANSPORT AND STORAGE OF SAMPLES AND DOCUMENTATION**

8.3.1. INASPOC has authorized a transport system that ensures Samples and Documentation will be transported in a manner that protects their integrity, identity and security.

- 8.3.2. Samples shall always be transported to the WADA- accredited laboratory using a INASPOC authorized transport method as soon as practicable after the completion of the Sample Collection Session. Samples shall be transported in a manner which minimizes the potential for Sample degradation due to factors such as time delay and extreme temperature variations. Samples will be transported to the laboratory at the completion of the Doping Control session and/or at designated pick-up times.
- 8.3.3. Documentation identifying the Athlete shall not be included with the Samples or documentation sent to the WADA-accredited laboratory or as otherwise approved by WADA.
- 8.3.4. INASPOC shall send all relevant Sample Collection Session Documentation to the APC using a INASPOC authorized transport method as soon as practicable after the completion of the Sample Collection Session.
- 8.3.5. When required, the DCO shall complete all necessary documentation for customs and courier transport purposes.
- 8.3.6. If the Samples with accompanying documentation of the Sample Collection Session documentation are not received at their respective intended destinations, or if a Sample's integrity or identity may have been compromised during transport INASPOC shall check the Chain of Custody, and APC shall consider whether the Samples should be voided.

8.3.7. The opening of the transport boxes by customs, border authorities or INASPOC security staff will not, in itself, invalid at laboratory results.

8.3.8. Documentation related to a Sample Collection Session and/or an anti-doping rule violation may be stored by the APC for a minimum often (10) years.

**9. OWNERSHIP OF SAMPLES**

- 9.1.** All Samples collected from Athletes are owned by the APC.
- 9.2.** The APC may transfer ownership of the samples to another Anti-Doping Organization upon request.

### **9.3. ANNEX**

## **ANNEX A: INVESTIGATING A POSSIBLE FAILURE TO COMPLY**

### **1. OBJECTIVE**

- 1.1.** ensure that any matters occurring before, during or after a Sample Collection Session that may lead to a determination of a Failure to Comply are assessed, acted upon and documented.

### **2. SCOPE**

- 2.1.** Investigating a possible Failure to Comply begins when the APC, INASPOC or a DCO becomes aware of a possible Failure to Comply and ends when the APC takes appropriate follow-up action based on the outcome of its investigation into the possible Failure to Comply.

### **3. RESPONSIBILITY**

- 3.1.** The APC is responsible for ensuring that:

- 3.1.1.** any matters with the potential to compromise an Athlete's test are assessed by means of an initial review according to the APC Anti-Doping Rules to determine if a possible Failure to Comply has occurred;
- 3.1.2.** all relevant information and documentation, including information from the immediate surroundings when applicable, is obtained as soon as possible or practical to ensure that all knowledge of the matter can be reported and be presented as possible evidence;

3.1.3. appropriate documentation is completed to report any possible Failure to Comply;

3.1.4. the Athlete or other Person is informed of the possible Failure to Comply in writing and has the opportunity to respond; and

3.1.5. the final determination is made available to other Anti-Doping Organizations in accordance with the Code.

**3.2.** The DCO is responsible for:

3.2.1. informing the Athlete or other Person that a Failure to Comply could result in an anti-doping rule violation;

3.2.2. completing the Athlete's Sample Collection Session where possible; and

3.2.3. providing a detailed written report of any possible Failure to Comply.

**3.3.** The other Sample Collection Personnel are responsible for:

3.3.1. informing the Athlete or other Person that a Failure to comply could result in an anti-doping rule violation; and

3.3.2. reporting to the DCO any possible Failure to Comply

## **4. REQUIREMENTS**

**4.1.** Any potential Failure to Comply shall be reported by the DCO and/or followed up by the APC as soon as practical.

- 4.2.** If the APC determines that there has been a potential Failure to Comply, the Athlete or other Person shall be notified in the course of the initial review of:
- 4.2.1. the possible consequences; and
  - 4.2.2. that a potential Failure to Comply is being investigated by the APC and appropriate follow-up action will be taken.
- 4.3.** Any additional necessary information about the possible Failure to Comply shall be obtained from all relevant sources, including the Athlete or other Person, as soon as possible and recorded.
- 4.4.** The APC shall ensure that the outcomes of its initial review into the potential Failure to Comply are considered for results management action and, if applicable, for further planning and target testing.

## **ANNEX B: MODIFICATIONS FOR ATHLETES WITH IMPAIRMENTS**

### **1. OBJECTIVE**

- 1.1. To ensure that the special needs of Athletes with impairments are considered in relation to the provision of a Sample, where possible, without compromising the integrity of the Sample Collection Session.

### **2. SCOPE**

- 2.1. Determining whether modifications are necessary starts with identification of situations where sample collection involves Athletes with impairments and ends with modifications to Sample Collection Procedures and Equipment where necessary, and where possible.

### **3. RESPONSIBILITY**

- 3.1. INASPOC has responsibility for ensuring, when possible, that the DCO has any information and Sample Collection Equipment necessary to conduct a Sample Collection Session for Athletes with any impairment. The DCO has responsibility for Sample collection.

### **4. REQUIREMENTS**

- 4.1. All aspects of notification and sample collection for Athletes with impairments shall be carried out in accordance with the standard notification and sample collection procedures unless modifications are necessary due to the Athlete's impairment.
- 4.2. In planning or arranging sample collection, INASPOC and DCO shall consider whether there will be any sample collection for Athletes with impairments that may require modifications to the standard procedures for notification or sample

collection, including sample collection equipment and facilities.

- 4.3. The DCO shall have the authority to make modifications as the situation requires when possible and as long as such modifications will not compromise the identity, security or integrity of the Sample. All such modifications must be documented.
- 4.4. An Athlete with an intellectual, physical, or sensory impairment can be assisted by the Athlete's representative or Sample Collection Personnel during the Sample Collection Session if authorized by the Athlete and agreed to by the DCO.
- 4.5. The DCO can decide that alternative Sample Collection Equipment or facilities will be used when required to enable the Athlete to provide the Sample as long as the Sample's identity, security and integrity will not be affected.
- 4.6. Athletes who are using urine collection or drainage systems are required to eliminate existing urine from such systems before providing a urine Sample for analysis. Where possible, the existing urine collection or drainage system should be replaced with a new, unused catheter or drainage system prior to collection of the Sample. It is the responsibility of the Athlete to have the necessary equipment available for this purpose.
- 4.7. The DCO will record modifications made to the standard Sample collection procedures for Athletes with impairments, including any applicable modifications specified in the above actions

## **ANNEX C: MODIFICATIONS FOR ATHLETES WHO ARE MINORS**

### **1. OBJECTIVES**

- 1.1** To ensure that the needs of Athletes who are Minors are met in relation to the provision of a Sample, without compromising the integrity of the Sample Collection Session.

### **2. SCOPE**

- 2.1** Determining whether modifications are necessary starts with identification of situations where Sample collection involves Athletes who are Minors and ends with modifications to Sample collection procedures where necessary and where possible.

### **3. RESPONSIBILITY**

- 3.1** INASPOC has responsibility for ensuring, when possible, that the DCO has any information necessary to conduct a Sample Collection Session with an Athlete who is a Minor. This includes confirming wherever necessary that parental consent clauses are in place when arranging testing at an event.

### **4. REQUIREMENTS**

- 4.1** All aspects of notification and sample collection for Athletes who are Minors shall be carried out in accordance with the standard notification and Sample collection procedures unless modifications are necessary due to the Athlete being a Minor.
- 4.2** In planning or arranging sample collection, the APC, INASPOC and DCO shall consider whether there will be any sample collection for Athletes who are Minors that may

require modifications to the standard procedures for notification or sample collection.

- 4.3** The DCO and INASPOC shall have the authority to make modifications as the situation requires when possible, and as long as such modifications will not compromise the identity, security or integrity of the Sample.
- 4.4** Athletes who are Minors should be notified in the presence of an adult and may choose to be accompanied by a representative throughout the entire Sample Collection Session. The representative shall not witness the passing of a urine sample unless requested to do so by the Minor. The objective is to ensure that the DCO is observing the Sample provision correctly. Even if the Minor declines a representative, the APC, DCO or Chaperone, as applicable, shall consider whether another third-party ought to be present during notification of and/or collection of the Sample from the Athlete.
- 4.5** The DCO shall determine who (in addition to the Sample Collection Personnel) may be present during the collection of a Sample from an Athlete who is a Minor, namely a representative of the Minor to observe the Sample Collection Session (including observing the DCO when the Minor is passing the urine Sample, but not directly observing the passing of the urine sample unless requested to do so by the Minor) and the DCO's/Chaperone's representative, to observe the DCO/Chaperone when a Minor is passing a urine sample, but without the representative directly observing the passing of the Sample unless requested by the Minor to do so.

- 4.6** Should an Athlete who is a Minor decline to have a representative present during the Sample Collection Session; this should be clearly documented by the DCO. This does not invalidate the test but must be recorded. If a Minor declines the presence of a representative, the representative of the DCO/Chaperone must be present.
- 4.7** The preferred venue for all Out-of-Competition Testing of a Minor is a location where the presence of an adult is most likely, e.g., a training venue.
- 4.8** The APC and INASPOC shall consider the appropriate course of action when no adult is present at the Testing of an Athlete who is a Minor and shall accommodate the Athlete in locating a representative in order to proceed with Testing.

## **ANNEX D: COLLECTION OF URINE SAMPLES**

### **1. OBJECTIVE**

**1.1** To collect an Athlete's urine Sample in a manner that ensures:

**1.1.1** consistency with relevant principles of internationally recognized standard precautions in healthcare settings, so that the health and safety of the Athlete and Sample Collection Personnel are not compromised;

**1.1.2** the Sample meets the Suitable Specific Gravity for Analysis and the Suitable Volume of Urine for Analysis. Failure of a sample to meet these requirements in no way invalidates the suitability of the Sample for analysis. The determination of a sample's suitability for analysis is the decision of the relevant laboratory, in consultation with the APC;

**1.1.3** the Sample has not been manipulated, substituted, contaminated or otherwise tampered with in any way;

**1.1.4** the Sample is clearly and accurately identified; and

**1.1.5** the Sample is securely sealed in a tamper-evident kit.

### **2. SCOPE**

**2.1** The collection of a urine sample begins with ensuring the Athlete is informed of the Sample Collection Requirements and ends with discarding any residual urine remaining at the end of the Athlete's Sample Collection Session.

### **3. RESPONSIBILITY**

- 3.1** The DCO has the responsibility for ensuring that each sample is properly collected, identified and sealed. The DCO has the responsibility for directly witnessing the passing of the urine sample.

### **4. REQUIREMENTS**

- 4.1** The DCO shall ensure that the Athlete is informed of the requirements of the Sample Collection Session, including any modifications as provided for in Annex B: Modifications for Athletes with Impairments.
- 4.2** The DCO shall ensure that the Athlete is offered a choice of appropriate equipment for collecting the Sample. If the nature of an Athlete's disability requires that he/she must use additional or other equipment as provided for in Annex B: Modifications for Athletes with Impairments, the DCO shall inspect that equipment to ensure that it will not affect the identity or integrity of the Sample.
- 4.3** The DCO shall instruct the Athlete to select a collection vessel.
- 4.4** When the Athlete selects a collection vessel and for selection of all other Sample Collection Equipment that directly holds the Urine Sample, the DCO will instruct the Athlete to check that all seals on the selected equipment are intact and the equipment has not been tampered with. If the Athlete is not satisfied with the selected equipment, he/she may select another. If the Athlete is not satisfied with any of the equipment available for the selection, this shall be recorded by the DCO. The DCO shall consult with the DVM/Lead DCO and Chairman of the APC Anti-Doping Committee on whether the Sample Collection Session shall continue with the existing equipment

provided or to terminate the session.

- 4.5** The Athlete shall retain control of the collection vessel and any sample provided until the Sample is sealed, unless assistance is required by an Athlete's disability as provided for in Annex B: Modifications for Athletes with Impairments. Additional assistance may be provided in exceptional circumstances to any Athlete by the Athlete's representative or Sample Collection Personnel during the Sample Collection Session where authorized by the Athlete and agreed to by the DCO.
- 4.6** The DCO/Chaperone who witnesses the passing of the Sample shall be of the same gender as the Athlete providing the Sample.
- 4.7** The DCO/Chaperone should where practicable ensure the Athlete thoroughly washes his/her hands prior to the provision of the Sample.
- 4.8** The DCO/Chaperone and Athlete shall proceed to an area of privacy to collect a Sample.
- 4.9** The DCO/Chaperone shall ensure an unobstructed view of the Sample leaving the Athlete's body and must continue to observe the Sample after provision until the Sample is securely sealed. In order to ensure a clear and unobstructed view of the passing of the Sample, the DCO/Chaperone shall instruct the Athlete to remove or adjust any clothing which restricts the DCO's/Chaperone's clear view of Sample provision. The DCO/Chaperone shall ensure that all urine passed by the Athlete at the time of provision of the Sample is collected in the collection vessel.

- 4.10** The DCO shall verify, in full view of the Athlete, that a Suitable Volume of Urine for Analysis has been provided.
- 4.11** Where the volume of urine is insufficient, the DCO shall conduct a partial Sample collection procedure as prescribed in Annex E: Urine Samples – Insufficient Volume.
- 4.12** Once the volume of urine provided by the Athlete is sufficient, the DCO shall instruct the Athlete to select a Sample Collection Kit containing A and B bottles in accordance with Article 4.4
- 4.13** Once a Sample collection kit has been selected, the DCO and the Athlete shall check that all code numbers match and that this code number is recorded accurately by the DCO on the Doping Control Form. If the Athlete or DCO finds that the numbers are not the same, the DCO shall instruct the Athlete to choose another kit in accordance with Article The DCO shall record the matter
- 4.14** The Athlete shall pour the minimum Suitable Volume of Urine for Analysis into the B bottle (to a minimum of 30 mL), and then pour the remainder of the urine into the A bottle (to a minimum of 60 mL). The Suitable Volume of Urine for Analysis shall be viewed as an absolute minimum. If more than the minimum Suitable Volume of Urine for Analysis has been provided, the DCO shall ensure that the Athlete fills the A bottle to capacity as per the recommendation of the equipment manufacturer. Should there still be urine remaining, the DCO shall ensure that the Athlete fills the B bottle to capacity as per the recommendation of the equipment manufacturer. The DCO shall instruct the Athlete to ensure that a small amount

of urine is left in the collection vessel, explaining that this is to enable the DCO to test that residual urine.

**4.15** The Athlete shall then seal the A and B bottles as directed by the DCO.

The DCO shall check, in full view of the Athlete, that the bottles have been properly sealed.

**4.16** The DCO shall test the residual urine in the collection vessel to determine if the Sample has a Suitable Specific Gravity for Analysis. If the DCO's field reading indicates that the Sample does not have a Suitable Specific Gravity for Analysis, then the DCO shall follow Annex F: Urine Samples that do not meet the requirement for Suitable Specific Gravity for Analysis.

**4.17** Urine should only be discarded when both the A and B bottles have been filled to capacity and the residual urine has been tested. in accordance with Article 4.16.

**4.18** The DCO shall ensure that the Athlete has been given the option of requiring any residual urine not being sent for analysis, is discarded in full view of the Athlete.

## **ANNEX E: COLLECTION OF BLOOD SAMPLES**

### **1. OBJECTIVES**

To collect an Athlete's blood Sample in a manner that ensures:

- a) consistency with relevant principles of internationally recognized standard precautions in healthcare settings so that the health and safety of the Athlete and Sample Collection Personnel are not compromised;
- b) the Sample is of a quality and quantity that meets the relevant analytical guidelines;
- c) the Sample has not been manipulated, substituted, contaminated or otherwise tampered with in any way;
- d) the Sample is clearly and accurately identified; and
- e) the Sample is securely sealed.

### **2. SCOPE**

- 2.1.** The collection of a blood Sample begins with ensuring the Athlete is informed of the Sample collection requirements and ends with properly storing the Sample prior to dispatch for analysis at the WADA-accredited laboratory.

### **3. RESPONSIBILITIES**

- 3.1.** The DVM/DCO has the responsibility for ensuring that:
  - a) each Sample is properly collected, identified and sealed; and
  - b) all Samples have been properly stored and dispatched in accordance with the relevant analytical guidelines.
- 3.2.** The Blood Collection Officer (BCO) has the responsibility for collecting the blood Sample, answering related questions during the

provision of the Sample, and proper disposal of used blood sampling equipment not required for completing the Sample Collection Session.

#### **4. REQUIREMENTS**

- 4.1.** Procedures involving blood shall be consistent with the local standards and regulatory requirements regarding precautions in healthcare settings.
- 4.2.** Blood Sample Collection Equipment shall consist of: (a) a single Sample tube for blood profiling purposes; or (b) both an A and a B Sample tube for blood analysis; or (c) as otherwise specified by the relevant laboratory.
- 4.3.** The DCO shall ensure that the Athlete is informed of the requirements of the Sample collection, including any modifications as provided for in Annex B: Modifications for Athletes with Impairments.
- 4.4.** The DCO and Athlete shall proceed to the area where the Sample will be provided.
- 4.5.** The DCO shall ensure the Athlete is offered comfortable conditions in accordance with the WADA Guidelines for Blood Sample Collection, prior to providing a Sample.
- 4.6.** The DCO shall instruct the Athlete to select the Sample collection kit/s required for collecting the Sample and to check that the selected equipment has not been tampered with and the seals are intact. If the Athlete is not satisfied with a selected kit, he/she may select another. If the Athlete is not satisfied with any

kits and no others are available, this shall be recorded by the DCO.

- 4.7.** If the DCO does not agree with the Athlete that all of the available kits are unsatisfactory, the DCO shall instruct the Athlete to proceed with the Sample Collection Session. If the DCO agrees with the Athlete that all available kits are unsatisfactory, the DCO shall terminate the collection of the Athlete's blood Sample and this shall be recorded by the DCO.
- 4.8.** When a Sample collection kit has been selected, the DCO and the Athlete shall check that all code numbers match and that this code number is recorded accurately by the DCO. If the Athlete or DCO finds that the numbers are not the same, the DCO shall instruct the Athlete to choose another kit. The DCO shall record the matter.
- 4.9.** The Blood Collection Officer shall clean the skin with a sterile disinfectant wipe or swab in a location unlikely to adversely affect the Athlete or his/her performance and, if required, apply a tourniquet. The Blood Collection Officer shall take the blood Sample from a superficial vein into the tube. The tourniquet, if applied, shall be immediately removed after the venipuncture has been made.
- 4.10.** The amount of blood removed shall be adequate to satisfy the relevant analytical requirements for the Sample analysis to be performed.
- 4.11.** If the amount of blood that can be removed from the Athlete at the first attempt is insufficient, the Blood Collection Officer shall repeat the procedure. Maximum attempts shall be three. Should all attempts fail, then the Blood Collection Officer shall

inform the DCO. The DCO shall terminate the collection of the blood Sample and record this and the reasons for terminating the collection.

- 4.12.** The Blood Collection Officer shall apply a dressing to the puncture site(s).
- 4.13.** The Blood Collection Officer shall dispose of used blood sampling equipment not required for completing the Sample Collection Session in accordance with the required local standards for handling blood.
- 4.14.** If the Sample requires further on-site processing, such as centrifugation or separation of serum, the Athlete shall remain to observe the Sample until final sealing in a secure, tamper- evident kit.
- 4.15.** The Athlete shall seal his/her Sample into the Sample collection kit as directed by the DCO. In full view of the Athlete, the DCO shall check that the sealing is satisfactory.
- 4.16.** The sealed Sample shall be stored in a manner that protects its integrity, identity and security prior to /transport from the Doping Control Station to the WADA-accredited laboratory.
- 4.17.** The WADA Guidelines for Blood Sample Collection shall be a further source of information for blood collection and Testing.

## **ANNEX F: URINE SAMPLES - INSUFFICIENT VOLUME**

### **1. OBJECTIVE**

- 1.1. To ensure that where a Suitable Volume of Urine for Analysis is not provided, appropriate procedures are followed.

### **2. SCOPE**

- 2.1. The procedure begins with informing the Athlete that the Sample that he/she has provided is not of Suitable Volume for Urine Analysis and ends with the Athlete's provision of a Sample of sufficient volume.

### **3. RESPONSIBILITY**

- 3.1. The DCO has the responsibility for declaring the Sample volume insufficient; and for collecting the additional Sample(s) to obtain a combined Sample of sufficient volume.

### **4. REQUIREMENTS**

- 4.1. If the Sample collected is of insufficient volume, the DCO shall inform the Athlete that a further Sample shall be collected to meet the Suitable Volume of Urine for Analysis Requirements.
- 4.2. The DCO shall instruct the Athlete to select partial Sample Collection Equipment in accordance with Article 4.4 of Annex D: Collection of Urine Samples.
- 4.3. The DCO shall then instruct the Athlete to open the relevant equipment, pour the insufficient Sample into the new container and seal it as directed by the DCO. The DCO shall check, in full view of the Athlete, that the container has been properly sealed.

- 4.4. The DCO and the Athlete shall check that the equipment code number and the volume and identity of the insufficient Sample are recorded accurately by the DCO on the Doping Control Form. Either the Athlete or the DCO shall retain control of the sealed partial Sample.
- 4.5. While waiting to provide an additional Sample, the Athlete shall remain under continuous observation and be given the opportunity to hydrate.
- 4.6. When the Athlete is able to provide an additional Sample, the procedures for collection of the Sample shall be repeated as prescribed in Annex D: Collection of Urine Samples until a sufficient volume of urine is provided by combining the initial and additional Sample(s).
- 4.7. When the DCO is satisfied that the requirements for Suitable Volume of Urine for Analysis have been met, the DCO and Athlete shall check the integrity of the seal(s) on the container(s) containing the previously provided partial Sample(s). Any irregularity with the integrity of the seal(s) will be recorded by the DCO and investigated according to Annex A: Investigating a Possible Failure to Comply.
- 4.8. The DCO shall then direct the Athlete to break the seal(s) and combine the Samples, ensuring that additional Samples are added in the order they were collected to the original partial Sample until, as a minimum, the requirement for Suitable Volume of Urine for Analysis is met.

- 4.9.** The DCO and the Athlete shall then continue with Article 4.12 or Article 4.14 of Annex D: Collection of Urine Samples as appropriate.
- 4.10.** The DCO shall check the residual urine in accordance with Article 4.16 of Annex D: Collection of Urine Samples to ensure that it meets the requirement for Suitable Specific Gravity for Analysis.
- 4.11.** Urine should only be discarded when both the A and B bottles have been filled to capacity in accordance with Article 4.14 of Annex D: Collection of Urine Samples and the residual urine has been checked in accordance with Article 4.10 of this Annex E: Urine Samples - Insufficient Volume. The Suitable Volume of Urine for Analysis shall be viewed as an absolute minimum

## **ANNEX G: URINE SAMPLES THAT DO NOT MEET THE REQUIREMENT FOR SUITABLE SPECIFIC GRAVITY FOR ANALYSIS**

### **1. OBJECTIVE**

To ensure that when the urine Sample does not meet the requirement for Suitable Specific Gravity for Analysis, appropriate procedures are followed.

### **2. SCOPE**

The procedure begins with the DCO informing the Athlete that a further Sample is required and ends with the collection of a Sample that meets the requirements for Suitable Specific Gravity for Analysis, or appropriate follow-up action by the APC if required.

### **3. RESPONSIBILITY**

BAYPGOC is responsible for establishing procedures to ensure that a suitable Sample is collected. If the original Sample collected does not meet the requirements for Suitable Specific Gravity for Analysis, the DCO is responsible for collecting additional Samples until a suitable Sample is obtained.

### **4. REQUIREMENTS**

- 4.1.** The DCO shall determine that the requirements for Suitable Specific Gravity for Analysis have not been met.
- 4.2.** The DCO shall inform the Athlete that he/she is required to provide a further Sample.
- 4.3.** While waiting to provide additional Samples, the Athlete shall remain under continuous observation.

- 4.4. The Athlete shall be encouraged not to hydrate excessively, since this may delay the production of a suitable Sample. In appropriate circumstances, excessive hydration may be pursued as a violation of Code Article 2.5 (Tampering or Attempted Tampering with any part of Doping Control).
- 4.5. When the Athlete is able to provide an additional Sample, the DCO shall repeat the procedures for collection of the Sample as prescribed in Annex D: Collection of Urine Samples.
- 4.6. The DCO should continue to collect additional Samples until the requirement for Suitable Specific Gravity for Analysis is met, or until the DCO determines that there are exceptional circumstances, which means that, for logistical reasons, it is impossible to continue with the Sample Collection Session. Such exceptional circumstances shall be documented accordingly by the DCO.
- Note:** Minimum Volume of urine required for analysis will remain at 90ml and SG limit of 1.005 or above. However, if an athlete can provide 150ml or more of urine, the minimum specific gravity measurement will be lowered to 1.003 or above. If urine volume is >90ml but < 150ml, the current SG measurement of 1.005 will remain.
- 4.7. The DCO shall record that the Samples collected belong to a single Athlete and the order in which the Samples were provided.
- 4.8. The DCO shall then continue with the Sample Collection Session in accordance with Article 4.17 of Annex D: Collection of Urine Samples.

- 4.9.** If it is determined that none of the Athlete's Samples meets the requirement for Suitable Specific Gravity for Analysis and the DCO determines that for logistical reasons it's impossible to continue with the Sample Collection Session, the DCO shall consult the DVM/Lead DCO and Chair of the APC Anti-Doping Committee for a decision to end the Sample Collection Session. In such circumstances, if appropriate, the APC may investigate a possible anti-doping rule violation.
- 4.10.** The DCO shall send all Samples collected to the WADA-accredited laboratory for analysis, irrespective of whether or not they meet the requirements for Suitable Specific Gravity for Analysis.
- 4.11.** The WADA-accredited laboratory shall, in conjunction with the APC, determine which Samples shall be analyzed.

## **ANNEX H: SAMPLE COLLECTION PERSONNEL REQUIREMENTS**

### **1. OBJECTIVE**

To ensure that Sample Collection Personnel have no conflict of interest and have adequate qualifications and experience to conduct Sample Collection Sessions.

### **2. SCOPE**

Sample Collection Personnel requirements start with the development of the necessary competencies for Sample Collection Personnel and ends with the provision of identifiable accreditation.

### **3. RESPONSIBILITY**

INASPOC has the responsibility for all activities defined in this Annex G

### **4. REQUIREMENTS – QUALIFICATIONS AND TRAINING**

- 4.1.** INASPOC together with Indonesia Anti-Doping Organization (IADO) shall determine the necessary competence and qualification requirements for the positions of DCO and Chaperone. INASPOC shall develop duty statements for all Sample Collection Personnel that outline their respective responsibilities. As a minimum Sample Collection Personnel shall not be Minors.
- 4.2.** INASPOC shall ensure that the Sample Collection Personnel having an interest in the outcome of the collection or Testing of a Sample from any Athlete, who might provide a Sample at a session, will not be appointed to that Sample Collection Session. Sample Collection Personnel are deemed to have an interest in the collection of a Sample if they are:

- a) involved in the planning of the sport for which Testing is being conducted; or
- b) related to, or involved in, the personal affairs of any Athlete who might provide a Sample at that session.

**4.3.** INASPOC shall ensure that Sample Collection Personnel are adequately qualified and trained to carry out their duties.

**4.4.** The training program for DCOs as a minimum shall include:

- a) comprehensive theoretical training in different types of Testing activities relevant to the DCO position;
- b) observation of all Sample collection activities related to requirements in these Technical Procedures for Doping Control preferably on site; and
- c) the satisfactory performance of three complete Sample Collection Sessions on site under observation by a] qualified DCO, or similar. The requirement related to the actual passing of Sample shall not be included in the on- site observations.

**4.5.** The training program for Chaperones shall include studies of all relevant requirements of the Sample collection process.

**4.6.** INASPOC shall maintain the records of education, training, skills, and experience of all Sample Collection Personnel.

## **5. REQUIREMENTS – ACCREDITATION, RE-ACCREDITATION AND DELEGATION**

**5.1.** INASPOC shall accredit and re-accredit Sample Collection Personnel.

- 5.2.** INASPOC shall ensure that Sample Collection Personnel have completed the training program and are familiar with the requirements in these rules before granting accreditation.
- 5.3.** Accreditation shall only be valid for the duration of the Games.
- 5.4.** Only Sample Collection Personnel that have an accreditation recognized by INASPOC shall be authorized by INASPOC to conduct Sample Collection Activities on behalf of the APC, as the Sample Collection Authority (SCA).
- 5.5.** DCOs may personally perform any activities involved in the Sample Collection Session, with the exception of blood collection, or they may direct a Chaperone to perform specified activities that fall within the scope of the Chaperone's authorized duties.

## APPENDIX

### APPENDIX 1: DEFINITIONS

**ADAMS.** The Anti-Doping Administration and Management System is a Web-based database management tool for data entry, storage, sharing, and reporting designed to assist stakeholders and WADA in their anti- doping operations in conjunction with data protection legislation.

**Adverse Analytical Finding.** A report from a laboratory or other WADA-approved Testing entity that, consistent with the International Standard for Laboratories and related Technical Documents, identifies in a Sample the presence of a Prohibited Substance or its Metabolites or Markers (including elevated quantities of endogenous substances) or evidence of the Use of a Prohibited Method.

**Anti-Doping Organization.** A Signatory that is responsible for adopting rules for initiating, implementing or enforcing any part of the Doping Control process. This includes, for example, the International Olympic Committee, the International Paralympic Committee, other Major Event Organizations that conduct Testing at their Events, WADA, International Federations, and National Anti-Doping Organizations.

**Athlete.** For purposes of Doping Control, any Person who participates, or who may potentially participate, in the Event.

**Athlete Support Personnel.** Any coach, trainer, manager, agent, team staff, official, medical, para-medical personnel, parent or other Person working with, treating or assisting Athletes participating in or preparing for the Event.

**Attempt.** Purposely engaging in conduct that constitutes a substantial step in a course of conduct planned to culminate in the commission of an anti-doping rule violation. Provided, however, there shall be no anti-doping rule violation based solely on an Attempt to commit a violation if the Person renounces the Attempt prior to it being discovered by a third party not involved in the Attempt.

**Atypical Finding.** A report from a laboratory or other WADA-approved entity which requires further investigation as provided by the International Standard for Laboratories or related Technical Documents prior to the determination of an Adverse Analytical Finding.

**CAS.** The Court of Arbitration for Sport. **Code.** The World Anti-Doping Code.

**Competition.** A single race, match, game or singular athletic contest. For example, a basketball game or the finals of the Paralympic 100-meter of Men's T54 race in athletics. For stage races and other athletic contests where prizes are awarded on a daily or other interim basis the distinction between a Competition and an Event will be as provided in the rules of the applicable International Federation.

**Consequences of Anti-Doping Rules Violations.** An Athlete's or other Person's violation of an anti-doping rule may result in one or more of the following: (a) Disqualification means the Athlete's results in a particular Competition or Event are invalidated, with all resulting consequences including forfeiture of any medals, points and prizes; (b) Ineligibility means the Athlete or other Person is barred for a specified period of time from participating in any Competition or other activity or funding; and (c) Provisional Suspension means the Athlete or other

Person is barred temporarily from participating in any Competition prior to the final decision at a hearing conducted under Article 8.

**Doping Control.** All steps and processes from test distribution planning through to ultimate disposition of any appeal including all steps and processes in between such as provision of whereabouts information, Sample collection and handling, laboratory analysis, therapeutic use exemptions, results management and hearings.

**Event.** A series of individual Competitions conducted together under one ruling body (e.g., the Olympic Games, FINA World Championships, or Pan American Games).

**Event Period.** The time between the beginning and end of an Event, as established by the ruling body of the Event.

**In-Competition.** Unless provided otherwise in the rules of an International Federation or other relevant Anti-Doping Organization, “In-Competition” means the period commencing twelve hours before a Competition in which the Athlete is scheduled to participate through the end of such Competition and the sample collection process related to such Competition.

**In-Competition Period.** The Period of the event.

**Independent Observer Program.** A team of observers, under the supervision of WADA, who observe and may provide guidance on the Doping Control process at certain Events and report on their observations.

**Individual Sport.** Any sport that is not a Team Sport.

**International Event.** An Event where the International Olympic Committee, the International Paralympic Committee, an International Federation, a Major Event Organization, or another international sport organization is the ruling body for the Event or appoints the technical officials for the Event.

**International-Level Athlete.** Athletes designated by one or more International Federations as being within the Registered Testing Pool for an International Federation.

**International Standard.** A standard adopted by WADA in support of the Code. Compliance with an International Standard (as opposed to another alternative standard, practice or procedure) shall be sufficient to conclude that the procedures addressed by the International Standard were performed properly. International Standards shall include any Technical Documents issued pursuant to the International Standard.

#### **ASEAN Para Sports Federation**

The ASEAN regional organization of Paralympic Movement that function as the ruling body for ASEAN Para Games.

**Marker.** A compound, group of compounds or biological parameter(s) that indicates the Use of a Prohibited Substance or Prohibited Method.

**Indonesia ASEAN Para Games Organizing Committee (INASPOC).** The Organizing Committee for the ASEAN Para Games 2022.

**Metabolite.** Any substance produced by a biotransformation process.

**Minor.** A natural Person who has not reached the age of majority as established by the applicable laws of his or her country of residence.

**National Anti-Doping Organization.** The entity(ies) designated by each country as possessing the primary authority and responsibility to adopt and implement anti-doping rules, direct the collection of Samples, the management of test results, and the conduct of hearings, all at the national level. This includes an entity which may be designated by multiple countries to serve as regional Anti-Doping Organization for such countries. If this designation has not been made by the competent public authority(ies), the entity shall be the country's National Olympic Committee or its designee.

**National Paralympic Committee.** The organization recognized by the International Paralympic Committee.

**No Advance Notice.** A Doping Control which takes place with no advance warning to the Athlete and where the Athlete is continuously chaperoned from the moment of notification through Sample provision.

**No Fault or Negligence.** The Athlete's establishing that he or she did not know or suspect, and could not reasonably have known or suspected even with the exercise of utmost caution, that he or she had Used or been administered the Prohibited Substance or Prohibited Method

**No Significant Fault or Negligence.** The Athlete's establishing that his or her fault or negligence, when viewed in the totality of the circumstances and taking into account the criteria for No

Fault or Negligence, was not significant in relationship to the anti-doping rule violation.

**Out-of-Competition.** Any Doping Control which is not In-Competition. Participant. Any Athlete or Athlete Support Personnel.

**Period of the Surakarta 2022 ASEAN Para Game.** The period commencing on the date of the opening of the Official Games Hotel for the Event, namely, 25 July 2022 up until and including the day of the closing ceremony of the Event, namely, 6 August 2022.

**Person.** A natural Person or an organization or other entity.

**Possession.** The actual, physical Possession, or the constructive Possession (which shall be found only if the Person has exclusive control over the Prohibited Substance or Prohibited Method or the premises in which a Prohibited Substance or Prohibited Method exists); provided, however, that if the Person does not have exclusive control over the Prohibited Substance or Prohibited Method or the premises in which a Prohibited Substance or Prohibited Method exists, constructive Possession shall only be found if the Person knew about the presence of the Prohibited Substance or Prohibited Method and intended to exercise control over it. Provided, however, there shall be no anti-doping rule violation based solely on Possession if, prior to receiving notification of any kind that the Person has committed an anti-doping rule violation, the Person has taken concrete action demonstrating that the Person never intended to have Possession and has renounced Possession by explicitly declaring it to an Anti-Doping Organization. Notwithstanding anything to the contrary in this definition, the purchase (including by any electronic or other means) of a

Prohibited Substance or Prohibited Method constitutes Possession by the Person who makes the purchase.

**Prohibited List.** The List identifying the Prohibited Substances and Prohibited Methods.

**Prohibited Method.** Any method so described on the Prohibited List. Prohibited Substance. Any substance so described on the Prohibited List. Registered Testing Pool. The pool of top-level Athletes established separately by each International Federation and National Anti-Doping Organization who are subject to both In-Competition and Out-of-Competition Testing as part of that International Federation's or National Anti-Doping Organization's test distribution plan. Each International Federation shall publish a list which identifies those Athletes included in its Registered Testing Pool either by name or by clearly defined, specific criteria.

**Rules.** The APC Anti-Doping Rules 2021 applicable to the 11th ASEAN Para Games Surakarta 2022.

**Sample/Specimen.** Any biological material collected for the purposes of Doping Control.

**Signatories.** Those entities signing the Code and agreeing to comply with the Code, including the International Olympic Committee, International Federations, International Paralympic Committee, National Olympic Committees, National Paralympic Committees, Major Event Organizations, National Anti-Doping Organizations, and WADA.

**Tampering.** Altering for an improper purpose or in an improper way; bringing improper influence to bear; interfering improperly; obstructing, misleading or engaging in any fraudulent conduct to alter results or prevent normal procedures from occurring; or providing fraudulent information to an Anti-Doping Organization.

**Target Testing.** Selection of Athletes for Doping Control where specific Athletes or groups of Athletes are selected on a non-random basis for Doping Control at a specified time.

**Team Sport.** A sport in which the substitution of players is permitted during a Competition.

**Testing.** The parts of the Doping Control process involving test distribution planning, Sample collection, Sample handling, and Sample transport to the laboratory.

**Trafficking.** Selling, giving, transporting, sending, delivering or distributing a Prohibited Substance or Prohibited Method (either physically or by any electronic or other means) by an Athlete, Athlete Support Personnel or any other Person subject to the jurisdiction of an Anti-Doping Organization to any third party; provided, however, this definition shall not include the actions of bona fide medical personnel involving a Prohibited Substance used for genuine and legal therapeutic purposes or other acceptable justification, and shall not include actions involving Prohibited Substances which are not prohibited in Out-of-Competition Testing unless the circumstances as a whole demonstrate such Prohibited Substances are not intended for genuine and legal therapeutic purposes.

**UNESCO Convention.** The International Convention against Doping in Sport adopted by the 33rd session of the UNESCO General Conference on October 19th, 2005, including any all amendments adopted by the States Parties to the Convention and the Conference of Parties to the International Convention against Doping in Sport.

## APPENDIX 2: Therapeutic Use Exemptions Form



## Template of TUE Application Form

**Therapeutic Use Exemptions (TUE) Application Form**

Please complete all sections in capital letters or typing. Athlete to complete sections 1, 5, 6 and 7; physician to complete sections 2, 3 and 4. Illegible or incomplete applications will be returned and will need to be re-submitted in legible and complete form.

**1. Athlete Information**

Surname: _____		Given Names: _____	
Female <input type="checkbox"/>	Male <input type="checkbox"/>	Date of Birth (d/m/y): _____	
Address: _____			
City: _____		Country: _____	Postcode: _____
Tel.: _____ (with International code)		E-mail: _____	
Sport: _____		Discipline/Position: _____	
International or National Sport Organization: _____			
If you are an Athlete with an impairment, please indicate the impairment: _____ _____ _____			



## 2. Medical Information (continue on separate sheet if necessary)

Diagnosis:

If a permitted medication can be used to treat the medical condition, please provide clinical justification for the requested use of the prohibited medication:

### Comment:

Evidence confirming the diagnosis shall be attached and forwarded with this application. The medical information must include a comprehensive medical history and the results of all relevant examinations, laboratory investigations and imaging studies. Copies of the original reports or letters should be included when possible. Evidence should be as objective as possible in the clinical circumstances. In the case of non-demonstrable conditions, independent supporting medical opinion will assist this application.

WADA maintains a series of guidelines to assist physicians in the preparation of complete and thorough TUE applications. These TUE Physician Guidelines can be accessed by entering the search term "Medical Information" on the WADA website: <https://www.wada-ama.org>. The guidelines address the diagnosis and treatment of a number of medical conditions commonly affecting athletes, and requiring treatment with prohibited substances.

## 3. Medication Details

Prohibited Substance(s): <u>Generic name</u>	Dose	Route of Administration	Frequency	Duration of Treatment
1.				
2.				
3.				



## 4. Medical Practitioner's Declaration

I certify that the information at sections 2 and 3 above is accurate, and that the above-mentioned treatment is medically appropriate.

Name: \_\_\_\_\_

Medical specialty: \_\_\_\_\_

Address: \_\_\_\_\_

Tel.: \_\_\_\_\_

Fax: \_\_\_\_\_

E-mail: \_\_\_\_\_

Signature of Medical Practitioner: \_\_\_\_\_ Date: \_\_\_\_\_



### 5. Retroactive applications

<p><b>Is this a retroactive application?</b></p> <p><b>Yes:</b> <input type="checkbox"/></p> <p><b>No:</b> <input type="checkbox"/></p> <p>If yes, on what date was treatment started?</p> <p>_____</p> <p>_____</p>	<p><b>Please choose one:</b></p> <p><input type="checkbox"/> Emergency treatment or treatment of an acute medical condition was necessary</p> <p><input type="checkbox"/> Due to other exceptional circumstances, there was insufficient time or opportunity to submit an application prior to sample collection</p> <p><input type="checkbox"/> Advance application not required under applicable rules</p> <p><input type="checkbox"/> Fairness (WADA and [IF/NADO] approval required)</p> <p>Please explain:</p> <p>_____</p> <p>_____</p> <p>_____</p> <p>_____</p> <p>_____</p>
--	--



## 6. Previous applications

Have you submitted any previous TUE application(s) to any ADO?

Yes ☐

No ☐

For which substance or method?

\_\_\_\_\_

To whom? \_\_\_\_\_ When? \_\_\_\_\_

Decision: Approved ☐

Not approved ☐



## 7. Athlete's declaration

I, \_\_\_\_\_, certify that the information set out at sections 1, 5 and 6 is accurate. I authorize the release of personal medical information to the relevant Anti-Doping Organization (ADO) as well as to WADA authorized staff, to the WADA TUEC (Therapeutic Use Exemption Committee) and to other ADO TUECs and authorized staff that may have a right to this information under the World Anti-Doping Code ("Code") and/or the International Standard for Therapeutic Use Exemptions. These people are subject to a professional or contractual confidentiality obligation.

I consent to my physician(s) releasing to the above persons any health information that they deem necessary in order to consider and determine my application.

I understand that my information will only be used for evaluating my TUE request and in the context of potential anti-doping rule violation investigations and procedures. I understand that if I ever wish to (1) obtain more information about the use of my health information; (2) exercise any rights I may have, such as my right of access, rectification, restriction, opposition, or deletion; or (3) revoke the right of these organizations to obtain my health information, I must notify my medical practitioner and my ADO in writing of that fact. I understand and agree that it may be necessary for TUE-related information submitted prior to revoking my consent to be retained for the purpose of investigations or proceedings related to a possible anti-doping rule violation, where this is required by the *Code*, *International Standards*, or national anti-doping laws; or to establish, exercise or defend a legal claim involving me, WADA, and/or an ADO.

I consent to the decision on this application being made available to all ADOs, or other organizations, with Testing authority and/or results management authority over me.

I understand and accept that the recipients of my information and of the decision on this application may be located outside the country where I reside. In some of these countries data protection and privacy laws may not be equivalent to those in my country of residence. I understand that my information may be stored in ADAMS, which is hosted by WADA on servers based in Canada, and will be retained for the duration as indicated in the WADA International Standard for the Protection of Privacy and Personal Information (ISPPPI).

I understand that if I believe that my Personal Information is not used in conformity with this consent and the ISPPPI, I can file a complaint to WADA ([privacy@wada-ama.org](mailto:privacy@wada-ama.org)), or my national regulator responsible for data protection in my country.

I understand that the entities mentioned above may rely on and be subject to national anti-doping laws that override my consent or other applicable laws that may require information to be disclosed to local courts, law enforcement, or other public authorities. I can obtain more information on national anti-doping laws from my International Federation or National Anti-Doping Agency.

**Athlete's signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**Parent's/Guardian's signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

(If the Athlete is a Minor or has an impairment preventing him/her from signing this form, a parent or guardian shall sign on behalf of the Athlete)

Please submit the completed form to \_\_\_\_\_ by the following means (keeping a copy for your records): \_\_\_\_\_

## APPENDIX 3: ORGANIZATION

### APSF Medical and Sports science

**Chairperson** : Prof Dr. Than Than Hitay

### APC Medical and Sports Science Committee

**Chairperson** : Badrul Amini Abd Rashid, PhD

### TUE Committee Appointed by APC for the 11th ASEAN Para Games Solo 2022

**Chairperson** : Dr Monalisa Md Rasip (Malaysia)

**Members** : Dr Arie Soetopo, Sp. KO (Indonesia)  
Dr Sophia Benedicta Hage (Indonesia)

**Appointed By APSF** : Dr Mohd Apandi Yusof (Malaysia)

### Subdivision Anti-Doping INASPOC

**Chairperson** : dr Eka Wulan Sari, MARS

**Member** : Dra Linda Rosalina, Apt, M.Si  
Natashya Marcellina Ardiany, S.Pd, S.M, MA  
dr. Guntur Lawu Wibowo  
Adinda Laksmi Tiarasari B SH  
Heru Purnama  
Meify Bahar, S.Psi  
Weliza Agustina, S.Pd, S.P, M.Pd  
Wahyu Erfandy, S.Or., M.Pd  
Ramadan, S.Pd  
Dezard Syah Rahman

**The person in charge for Doping Control Operations during ASEAN Para Games XI Surakarta 2022**

dr Eka Wulan Sari, MARS

Telp: +62 877 8877 3582

Dra Linda Rosalina, Apt, M.Si

Telp: +62 812 878 90371



11<sup>TH</sup> ASEAN  
PARA GAMES  
SOLO 2022



# DOPING CONTROL GUIDE

Untuk ASEAN  
Para Games 2022  
Solo, Indonesia

Inaspor

Striving  
Equality